Disability

IntelGenx Announces FDA Approval of RIZAFILM® for the Treatment of Acute Migraine

Partner Gensco® Pharma preparing to commercially launch RIZAFILM® across the United States as soon as is practicableSAINT LAURENT, Quebec, April…

2 years ago

CloudMD Names Dhruv Chandra Chief Technology Officer to Accelerate Technological Advancement in Next Phase of Growth

CloudMD strengthens its commitment to innovation, exceptional customer experiences, data-driven insights, security, and complianceVANCOUVER, British Columbia, April 10, 2023 (GLOBE…

2 years ago

The Hazelden Betty Ford Foundation and TELUS Health collaborate to expand substance use disorder treatment and mental health support

CENTER CITY, Minn. and VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- The Hazelden Betty Ford Foundation and TELUS…

2 years ago

Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…

2 years ago

TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Human…

2 years ago

electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function…

2 years ago

GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray

New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic…

2 years ago

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),…

2 years ago